Research Study for NNC0113-5840 in Overweight or Obesity
This research study is looking at NNC0113-5840 to see if it is safe for treating people who are overweight or have obesity. You could join if you are between 18 and 55 years old and have a body mass index (BMI) between 25.0 and 34.9. In this study, you would receive either NNC0113-5840 or a placebo (a treatment with no active medicine), decided by chance. The main goal is to track any side effects you might experience. The study aims to enroll 48 participants to understand the safety of NNC0113-5840.
- Study design
- This is an interventional study where participants will be randomly assigned to receive either NNC0113-5840 or a placebo. It plans to enroll 48 participants.
- What's involved
- You would receive the study treatment, NNC0113-5840 or placebo, as an injection under the skin in your abdomen. The study will track your health up to day 43 after your first dose.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your health will be monitored for treatment-related side effects from the first day of dosing up to day 43.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of treatment emergent adverse events (TEAEs)From time of dosing (day 1) up to day 43
Measured as number of events.